Halozyme Therapeutics Stock Price Prediction

HALO Stock  USD 39.12  0.15  0.38%   
As of today, the RSI of Halozyme Therapeutics' share price is approaching 45. This usually indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Halozyme Therapeutics, making its price go up or down.

Oversold Vs Overbought

45

 
Oversold
 
Overbought
Halozyme Therapeutics stock price prediction is an act of determining the future value of Halozyme Therapeutics shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of Halozyme Therapeutics' future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of Halozyme Therapeutics and does not consider all of the tangible or intangible factors available from Halozyme Therapeutics' fundamental data. We analyze noise-free headlines and recent hype associated with Halozyme Therapeutics, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting Halozyme Therapeutics' stock price prediction:
Quarterly Earnings Growth
0.546
EPS Estimate Next Quarter
0.87
EPS Estimate Current Year
3.69
EPS Estimate Next Year
4.56
Wall Street Target Price
51.11
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of Halozyme Therapeutics based on different types of headlines from major news networks to social media. The Halozyme stock price prediction module provides an analysis of price elasticity to changes in media outlook on Halozyme Therapeutics over a specific investment horizon. Using Halozyme Therapeutics hype-based prediction, you can estimate the value of Halozyme Therapeutics from the perspective of Halozyme Therapeutics response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Halozyme Therapeutics using Halozyme Therapeutics' stock options and short interest. It helps to benchmark the overall future attitude of investors towards Halozyme using crowd psychology based on the activity and movement of Halozyme Therapeutics' stock price.

Halozyme Therapeutics Short Interest

A significant increase or decrease in Halozyme Therapeutics' short interest from the previous month could be a good indicator of investor sentiment towards Halozyme. Short interest can provide insight into the potential direction of Halozyme Therapeutics stock and how bullish or bearish investors feel about the market overall. An investor who is long Halozyme Therapeutics may also wish to track short interest. As short interest increases, investors should be becoming more worried about Halozyme Therapeutics and may potentially protect profits, hedge Halozyme Therapeutics with its derivative instruments, or be ready for some potential downside.
200 Day MA
38.8148
Short Percent
0.084
Short Ratio
8.17
Shares Short Prior Month
8.2 M
50 Day MA
39.5766

Halozyme Therapeutics Hype to Price Pattern

Investor biases related to Halozyme Therapeutics' public news can be used to forecast risks associated with an investment in Halozyme. The trend in average sentiment can be used to explain how an investor holding Halozyme can time the market purely based on public headlines and social activities around Halozyme Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Halozyme Therapeutics' market sentiment to its price can help taders to make decisions based on the overall investors consensus about Halozyme Therapeutics.

Halozyme Therapeutics Implied Volatility

    
  44.86  
Halozyme Therapeutics' implied volatility exposes the market's sentiment of Halozyme Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Halozyme Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Halozyme Therapeutics stock will not fluctuate a lot when Halozyme Therapeutics' options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in Halozyme Therapeutics. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in Halozyme Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Halozyme because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Halozyme Therapeutics after-hype prediction price

    
  USD 39.39  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Halozyme Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Halozyme Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
35.2145.2246.92
Details
Naive
Forecast
LowNextHigh
36.6938.3940.08
Details
11 Analysts
Consensus
LowTargetHigh
47.2351.9057.61
Details
Earnings
Estimates (0)
LowProjected EPSHigh
0.630.700.83
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Halozyme Therapeutics. Your research has to be compared to or analyzed against Halozyme Therapeutics' peers to derive any actionable benefits. When done correctly, Halozyme Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Halozyme Therapeutics.

Halozyme Therapeutics After-Hype Price Prediction Density Analysis

As far as predicting the price of Halozyme Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Halozyme Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Halozyme Therapeutics, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Halozyme Therapeutics Estimiated After-Hype Price Volatility

In the context of predicting Halozyme Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Halozyme Therapeutics' historical news coverage. Halozyme Therapeutics' after-hype downside and upside margins for the prediction period are 37.69 and 41.09, respectively. We have considered Halozyme Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
39.12
39.39
After-hype Price
41.09
Upside
Halozyme Therapeutics is very steady at this time. Analysis and calculation of next after-hype price of Halozyme Therapeutics is based on 3 months time horizon.

Halozyme Therapeutics Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Halozyme Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Halozyme Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Halozyme Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.23 
1.70
  0.29 
  0.14 
11 Events / Month
15 Events / Month
In about 11 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
39.12
39.39
0.69 
133.86  
Notes

Halozyme Therapeutics Hype Timeline

Halozyme Therapeutics is currently traded for 39.12. The entity has historical hype elasticity of 0.29, and average elasticity to hype of competition of -0.14. Halozyme is expected to increase in value after the next headline, with the price projected to jump to 39.39 or above. The average volatility of media hype impact on the company the price is about 133.86%. The price boost on the next news is projected to be 0.69%, whereas the daily expected return is currently at 0.23%. The volatility of related hype on Halozyme Therapeutics is about 274.19%, with the expected price after the next announcement by competition of 38.98. The company reported the previous year's revenue of 829.25 M. Net Income was 281.59 M with profit before overhead, payroll, taxes, and interest of 454.2 M. Given the investment horizon of 90 days the next expected press release will be in about 11 days.
Check out Halozyme Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.

Halozyme Therapeutics Related Hype Analysis

Having access to credible news sources related to Halozyme Therapeutics' direct competition is more important than ever and may enhance your ability to predict Halozyme Therapeutics' future price movements. Getting to know how Halozyme Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Halozyme Therapeutics may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
AGIOAgios Pharm 0.30 11 per month 1.48  0.17  7.26 (3.27) 15.13 
INSMInsmed Inc(0.76)9 per month 0.00 (0.09) 4.77 (4.32) 10.88 
CERECerevel Therapeutics Holdings 0.07 10 per month 0.00 (0.15) 1.09 (0.79) 5.25 
RAREUltragenyx(3.15)9 per month 2.73 (0.01) 4.25 (4.00) 15.57 
BMRNBiomarin Pharmaceutical(1.00)11 per month 1.16 (0.07) 1.95 (2.32) 5.18 
SGENSeagen Inc(0.31)8 per month 0.17  0.07  1.20 (0.63) 5.21 
ALNYAlnylam Pharmaceuticals(2.48)9 per month 0.00 (0.20) 3.14 (3.20) 13.33 
EXELExelixis(0.05)12 per month 1.80 (0.02) 1.84 (1.99) 9.57 
ALECAlector(0.43)8 per month 0.00 (0.05) 5.96 (6.31) 16.43 
LEGNLegend BiotechCorp(2.49)10 per month 0.00 (0.13) 4.46 (3.50) 12.61 
ASNDAscendis Pharma AS(2.01)10 per month 1.95  0.03  3.80 (3.31) 14.42 
CYTKCytokinetics(0.22)8 per month 0.00 (0.14) 3.99 (3.79) 13.75 
EWTXEdgewise Therapeutics 0.06 7 per month 3.09  0.06  6.17 (5.19) 29.95 
APLSApellis Pharmaceuticals(1.61)11 per month 0.00 (0.16) 3.12 (6.72) 16.59 
BPMCBlueprint Medicines Corp 3.22 10 per month 3.03  0.05  4.99 (4.78) 19.44 
BGNEBeiGene(1.79)10 per month 0.00 (0.08) 6.15 (4.39) 19.31 
INBXInhibrxInc 0.10 7 per month 1.42 (0.04) 2.25 (1.84) 15.38 
PTGXProtagonist Therapeutics(0.35)7 per month 2.45  0.02  5.83 (4.29) 21.15 
DICEDice Molecules Holdings(0.24)10 per month 1.07  0.07  2.83 (2.88) 37.64 
LRMRLarimar Therapeutics(0.36)11 per month 4.38  0.11  11.62 (6.45) 52.23 
VRDNViridian Therapeutics 0.48 7 per month 0.00 (0.15) 5.02 (5.75) 16.92 

Halozyme Therapeutics Additional Predictive Modules

Most predictive techniques to examine Halozyme price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Halozyme using various technical indicators. When you analyze Halozyme charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Halozyme Therapeutics Predictive Indicators

The successful prediction of Halozyme Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Halozyme Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Halozyme Therapeutics based on analysis of Halozyme Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Halozyme Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Halozyme Therapeutics's related companies.
 2021 2022 2023 2024 (projected)
Dividend Yield0.0022170.0027650.003180.005895
Price To Sales Ratio12.7611.85.885.59

Story Coverage note for Halozyme Therapeutics

The number of cover stories for Halozyme Therapeutics depends on current market conditions and Halozyme Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Halozyme Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Halozyme Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Halozyme Therapeutics Short Properties

Halozyme Therapeutics' future price predictability will typically decrease when Halozyme Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Halozyme Therapeutics often depends not only on the future outlook of the potential Halozyme Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Halozyme Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding134.2 M
Cash And Short Term Investments336 M
When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock:
Check out Halozyme Therapeutics Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Halozyme Stock analysis

When running Halozyme Therapeutics' price analysis, check to measure Halozyme Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Halozyme Therapeutics is operating at the current time. Most of Halozyme Therapeutics' value examination focuses on studying past and present price action to predict the probability of Halozyme Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Halozyme Therapeutics' price. Additionally, you may evaluate how the addition of Halozyme Therapeutics to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Is Halozyme Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.546
Earnings Share
2.1
Revenue Per Share
6.286
Quarterly Revenue Growth
0.267
Return On Assets
0.1189
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.